

CASE REPORT

Open Access

Breakpoint characterization of a novel large intragenic deletion of *MUTYH* detected in a MAP patient: Case report

Giovana T Torrezan¹, Felipe CC da Silva¹, Ana CV Krepischi^{1,2}, Érika MM Santos¹, Fábio de O Ferreira³, Benedito M Rossi⁴ and Dirce M Carraro^{1,2*}

Abstract

Background: *MUTYH*-associated polyposis (MAP) is a recessive, hereditary, colorectal cancer-predisposing syndrome caused by biallelic mutations in the *MUTYH* gene. Most *MUTYH* pathogenic variants are missense mutations, and until recently no gross genomic deletions had been described.

Case Presentation: We have identified a large deletion in the *MUTYH* gene: a > 4.2 kb deletion encompassing exons 4-16. This is the second description of this rearrangement, which has been recently described as the first large deletion in this gene. The clinically suspected MAP patient was homozygous for this mutation and presented with no amplification products for 14 exons of *MUTYH* on initial screening. Deletion breakpoints were refined to base pair level through array comparative genomic hybridization (aCGH) analysis followed by sequencing. The identified breakpoints were located within intron 3 and 146 bp downstream of the 3' end of the gene, with the presence of an *Alu*Jr element adjacent to the distal breakpoint. The presence of a 2 bp insertion at the junction suggests the involvement of the non-homologous end joining (NHEJ) repair mechanism, possibly facilitated by rearrangement-promoting elements. Examination of the *MUTYH* locus revealed a high *Alu* density that may make this region prone to rearrangements.

Conclusion: Large deletions are a possible mechanism for loss of function of the *MUTYH* gene, and investigation of such mutations may be important in identifying causative mutations in MAP patients.

Background

MUTYH-associated polyposis (MAP) (MIM#608456), a recessive inherited syndrome characterized by colorectal adenomatous polyposis and a high risk of colorectal cancer, is a disorder caused by biallelic pathogenic germline variants in the *human mutY homologue (MUTYH)* gene [1]. *MUTYH* spans 11.2 kb on chromosome 1p34.1 [2] and encodes a DNA glycosylase that plays a key role in base excision repair (BER) of 8-oxoG: A mismatches by removing the mismatched adenine [3]. The oxidation product 8-oxoG is the most stable product of oxidative DNA damage [4], which can lead to G: C to T:A transversions if not repaired⁵. Tumorigenesis

in MAP patients is thought to be initiated by somatic G: C → T:A transversions in *KRAS* and/or *APC* [5].

The clinical manifestations of MAP resemble familial adenomatous polyposis (FAP; MIM#175100), which is caused by autosomal dominantly inherited pathogenic variants in the *APC* gene. Most biallelic *MUTYH* mutation carriers have between ten and several hundred polyps, usually with later onset compared to FAP patients [1,6]. Also, a number of MAP patients with CRC and no polyps have been reported [5]. Mutations in *MUTYH* account for approximately 40% of patients with 10-100 colorectal adenomas (attenuated FAP patients) and positive familial history, a proportion slightly higher than that of *APC* mutations in these patients (30%) [7].

Nearly 300 different sequence variants have been identified so far in this gene (*MUTYH* Leiden Open Variation Database; <http://chromium.liacs.nl/LOVD2/>)

* Correspondence: dirce.carraro@accamargo.org.br

¹International Center of Research and Training (CIPE), A. C. Camargo Hospital, São Paulo, SP, Brazil

Full list of author information is available at the end of the article

colon_cancer/home.php?select_db=MUTYH). In contrast to pathogenic *APC* variants, which mostly result in a truncated or absent protein, most pathogenic *MUTYH* variants are missense variants and only a minority consists of splice site and truncating variants [2]. The two hotspot mutations p.Tyr179Cys (exon 7) and p.Gly396Asp (exon 13) are prevalent in populations of European origin, probably due to a founder effect, and account for approximately 80% of all reported mutant alleles [5,8]. In the Brazilian population, a recently published paper on patients with clinical phenotypes of MAP, FAP and Lynch syndrome identified 4/60 (6.6%) patients with these two hotspot mutations in a biallelic state [9]. Until recently, no gross genomic deletions or duplications had been described in this gene in any population.

Here, we report a case study in which we have characterized a large *MUTYH* deletion in a MAP patient. During the composition of this manuscript, an independent study performed by a French group identified this same rearrangement in one of their polyposis patients [10]. We have refined the breakpoint of this > 4.2 kb deletion to the base pair level. Based on the analysis of the sequences at breakpoints, we suggest a possible mechanism of origin for this alteration. Presence of this deletion was also analyzed in familial colorectal patients and a control group.

Case Presentation

A Brazilian female patient (FAP15) from the Hereditary Colorectal Cancer Registry of Hospital AC Camargo (São Paulo, Brazil), who was clinically suspected for MAP, was screened for mutations in the *MUTYH* gene

by direct sequencing. The age at onset of the attenuated polyposis (approximately 40 polyps) was 42 years and of the rectal cancer was 44 years. No extracolonic manifestations were observed in this patient. Family history was accessed through personal report. The patient stated that she had unaffected deceased parents, four unscreened siblings (without colonoscopy) and one affected sister from whom biological material was unavailable due to residence distance (Figure 1). The affected sister presented with attenuated polyposis at the age of 44 years. The proband had a Caucasian ancestry, since her great-grandparents were Portuguese.

In addition, the presence of this *MUTYH* deletion was screened through PCR in other 183 Brazilian individuals: three *APC/MUTYH*-mutation negative and 18 *APC/MUTYH*-mutation positive polyposis patients (12 *APC* mutation carriers, 5 *MUTYH* biallelic and one *MUTYH* monoallelic mutation carriers); 51 clinically suspected Lynch syndrome patients (fulfilling Amsterdam II or Bethesda criteria), who were non-carriers of germline mutations in the mismatch repair (MMR) genes *MLH1*, *MSH2*, *MSH6* and *PMS2*; and 111 healthy controls. Written informed consent was obtained from all patients and controls. This study was approved by the ethics committee of A. C. Camargo Hospital (approval number: 1169/08-B).

Identification and characterization of the deletion

We detected a homozygous deletion encompassing several exons of the *MUTYH* gene in this MAP patient. Genomic DNA was obtained from blood using the Puregene Genomic DNA Isolation Kit (Gentra Systems, USA) according to manufacturer's instructions.





Figure 1 Family tree of patient FAP15. The proband is indicated by the arrow. The proband's age at onset of the polyposis (42 years) and of the rectal cancer (44 years) are indicated. The patient presented unaffected deceased parents, four unscreened (without colonoscopy) siblings and one affected sister. The affected sister presented with polyposis at the age of 44 years. The Caucasian patient stated having Portuguese great-grandparents and no report of inbreeding in her family.

Eleven primer pairs were designed to amplify all 16 exons of *MUTYH* gene (NM_001128425.1), including intron-exon boundaries. Primers used for these analyses and PCR conditions are available upon request. Unexpected results were observed when performing standard PCR for *MUTYH* mutation screening on this patient; exons 3-16 could not be amplified (data not shown). As a positive control for the reaction, multiplex PCR in the presence of primers for control genes (*GAPDH* intron 7; *HPRT1* exon 3) was performed for each *MUTYH* exon and confirmed the absence of genomic template for this gene. The results of multiplex PCR for the patient and a control DNA are shown in Figure 2A.

With the purpose of elucidating the extent of the deletion, comparative genomic hybridization based on microarrays (aCGH) was performed. Briefly, samples were labeled with Cy3- and Cy5-dCTPs by random priming. Experiments were performed in duplicate using a 180 K whole-genome platform (OGT Technologies). Purification, hybridization, and washing were performed as recommended by the manufacturer. Data extraction was conducted using the Feature Extraction software (Agilent Technologies). We applied the Genomic Workbench software (Agilent Technologies) for identifying the constitutive genomic imbalances using the statistical algorithm ADM-2, with a sensitivity threshold of 6.7, a threshold \log_2 ratio of 0.4 or 1.1 for duplication or high



copy number gain, and -0.4 and -1.1 for deletion and homozygous loss, respectively.


Data analysis detected two sequences mapped within the *MUTYH* gene that exhibited \log_2 ratio values compatible with a homozygous deletion (oligoprobes A_14_P107667, mapped at chr1:45794902-45794961, and A_14_P122926, at chr1:45797594-45797640; coordinates given according to UCSC Feb. 2009 (GRCh37/hg19) assembly) (Figure 2B). Oligoprobes flanking the deletion at the 5' end of *MUTYH* gene sequence and downstream of the 3' end had \log_2 ratios values consistent with two copies (A_14_P122926-chr1:45804348-45804405, and A_14_P118536-chr1:45793780-45793830) (Figure 2B). Using an exon 2 forward primer (5'-GGTGGATGAGAGGGAGATAG-3') and reverse primers designed on the position of the A_14_P118536 undelated probe and 600 bp upstream (primers 16R2: 5'-CTTCAGGTCTTCACCAAGTCC-3' and 16R1: 5'-CTTCTCCTGTGCTTCCTCTC-3', respectively), we successfully amplified the junction fragments for this deletion. After confirming that the primer 16R1 was located at an undelated region and as it was closest to the breakpoint, further analyses were performed only with this primer. The PCR reaction of the control DNA pool failed to amplify any detectable PCR product (theoretically 5889 bp in length), whereas PCR products of \approx 1600 bp were detected using genomic DNA from the patient (Figure 2E). Briefly, the PCR conditions consisted of 25 ng of genomic DNA, 0.3 μ mol of each primer and 1X Platinum[®] PCR SuperMix High Fidelity (Invitrogen) in a 20 μ L reaction. Cycling conditions entailed a preincubation at 95°C for 2 minutes followed by 35 cycles of denaturation at 95°C for 20 seconds, annealing at 62°C and extension at 72°C for 2 minutes. Direct sequencing of the junction fragments identified the exact breakpoints (genomic position: chr1:g.45,794,768_45,799,052del4285insTA, cDNA position: c.348+33_*64+146del4285insTA), the precise size of the deletion interval (4,285 kb) and the affected exons (4-16) (Figure 2C and 2D). Genomic positions were confirmed using MUTALYZER 2.0 software. Previously, exon 3 appeared to be deleted in the PCR analysis because the breakpoint is located upstream of the reverse primer site. No region of the adjacent *HPDL* gene is deleted downstream of the 3' end of *MUTYH*.

As the patient investigated in this study presented a homozygous mutation and reported no inbreeding in her family, we examined the presence of this deletion among 111 healthy controls, 21 polyposis patients and 51 patients with familial CRC negative for mutations on MMR genes. The junction fragment could not be amplified from the DNA of any other patient or control (data not shown). One possible explanation for the homozygous occurrence of the deletion in this patient, without

consanguineous parents, is the inheritance of two alleles of a founder mutation in the population. The proband's great-grandparents were Portuguese, therefore she had Caucasian ancestry. In this sense, very recently this same deletion was found in a European MAP patient in compound heterozygosity with the common *MUTYH* Caucasian mutation p.Gly396Asp [10]. The description of the same rearrangement in patients from different geographic regions is a very exciting discovery and additional studies to uncover the origin and frequency of this mutation would be of great value. Another potential explanation for the homozygosity is the occurrence of isodisomy, a type of uniparental disomy that results in two identical segments from one parental homologue and can occur due to a recombination event in the zygote, though the existence of an affected sibling does not support this hypothesis.

Analysis of the junction sequence revealed several important features, including an insertion of 2 bp of non-template DNA (Figure 2F), several recombination motifs such as GCG and GAS [11] and the presence of an *Alu*Jr element located 2 bases upstream of the distal breakpoint (Figure 2G). No repetitive element is present at the upstream breakpoint. Examination of the *MUTYH* locus using the Repeat-Masker software <http://www.repeatmasker.org/> revealed an *Alu* density of 22.2% for an 11,800 kb region (chr1:45,794,343-45,806,142), which includes the entire gene (11,229 bp), and 571 bp downstream, which encompasses the distal breakpoint characterized in this study (Figure 3).

This study is particularly important from both a clinical and research perspective because we have identified the first large intragenic deletion in *MUTYH*: a 4.285 kb homozygous deletion in a MAP patient (c.[348+33_*64+146del4285insTA];[348+33_*64+146del4285insTA]). This mutation was submitted to the *MUTYH* LOVD Mutation Database and has been publicly available since May 12th: http://chromium.liacs.nl/LOVD2/colon_cancer/variants.php?select_db=MUTYH&action=view&view=1012041%2C0002450%2C10. The patient presented a homozygous deletion encompassing exons 4 to 16 detected and mapped through PCR, aCGH and sequencing. Breakpoints were sequenced and analysis of the junction sequence allowed us to postulate that classical nonhomologous end joining (NHEJ) is the most likely mechanism responsible for the deletion, as a 2-bp non-template insertion sequence is observed at the breakpoint junction [12,13]. This repair process involves the double strand breakage of DNA followed by end joining in the absence of extensive sequence homology, and is associated with small insertions at the junction sites [14] and with very short stretches of sequence identity (a few bp) between the two ends of the breakpoint junctions [15]. Analysis of breakpoints



surrounding sequences revealed the presence of an *AluJr* adjacent to the distal breakpoint and the existence of recombination/deletion promoting motifs [11] such as GAG and GCS trinucleotides. These motifs are known DNA polymerase pause-site core elements [16] and might have facilitated deletion.

In silico analysis of the *Alu* content in the *MUTYH* gene region revealed a high ratio of *Alu* sequences per kb, with *Alu* elements occurring once in every 1.8 kb (22.2%) when compared with the average of the human genome where *Alu* elements account for about 10% and occur once every 3 kb [17]. A recent study of more than 20 genes found evidence that a high content of transposable elements causes increased frequency of gene disruption by gross deletions in human disease [18]. Additionally, the local enrichment of *Alus* has been observed in regions with recurrent *Alu*-mediated rearrangements, e.g., the *VHL* locus in von Hippel-Lindau disease patients [19], and in genes implicated in colorectal cancer-predisposing disorders such as Lynch and Peutz-Jeghers syndromes (*EPCAM-MSH2* [20] and *STK11* [21], respectively). However, not every *Alu*-rich gene is prone to this type of deletion formation. Examples include the thymidine kinase or β -tubulin genes [20,22]. In the *MUTYH* gene, a recent study has shown that a polymorphic *AluY* insertion in intron 15 when in a homozygous state, leads to a 2.15 fold increase in the levels of 8-oxoG in leukocyte DNA and is associated with type 2 diabetes mellitus [23]; however, this insertion has not yet been studied in the context of colorectal cancer.

Conclusions

Currently, there is no information on the percentage of defects in the *MUTYH* gene caused by deletions/duplications of complete exons, and screening for this type of mutation is not a common practice as it is with the *APC* gene. Our finding highlights the importance of performing screening methods, such as qPCR, MLPA or long-range PCR, for large *MUTYH* deletions in polyposis patients. Furthermore, it remains to be addressed

whether the high density of *Alu* elements in this gene can cause an elevated frequency of *Alu*-mediated deletions and rearrangements. Nevertheless, the evidence shown here suggests that deletions could represent an important mechanism of loss of function in the *MUTYH* gene.

Consent

Written informed consent was obtained from all patients and controls for publication of this case report and any accompanying images. Copies of the written consents are available for review by the Editor-in-Chief of this journal.

Acknowledgements and Funding

The authors acknowledge the patients for their collaboration, the Nucleic Acid Bank of A. C. Camargo Hospital for sample processing and Bianca C. G. Lisboa for guidance in establishing the sequencing protocols. This work was supported by National Institute of Science and Technology in Oncogenomics (INCITO)-FAPESP: 2008/57887-9.

Author details

¹International Center of Research and Training (CIPE), A. C. Camargo Hospital, São Paulo, SP, Brazil. ²National Institute of Science and Technology in Oncogenomics (INCITO), São Paulo, SP, Brazil. ³Colorectal Tumors Department, A. C. Camargo Hospital, São Paulo, SP, Brazil. ⁴Barretos Cancer Hospital-Pio XII Foundation, Barretos, São Paulo, Brazil.

Authors' contributions

GTT designed and performed the molecular genetic studies and drafted the manuscript. FCCS participated in the experimental design and revised the manuscript critically. ACVK carried out the aCGH analysis and revised the manuscript critically. EMMS participated in the clinical data acquisition and analysis. FOF conceived the study, and participated in its coordination. BMR conceived of the study, and participated in its design. DMC participated in its experimental design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 6 July 2011 Accepted: 30 September 2011

Published: 30 September 2011

References

1. Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, Hodges AK, Davies DR, David SS, Sampson JR, Cheadle JP: **Inherited variants of MYH associated with somatic G:C -> T:A mutations in colorectal tumors.** *Nat Genet* 2002, **30**(2):227-32.

2. Out AA, Tops CMJ, Nielsen ÅM, Weiss MM, Minderhout IJHMV, Fokkema IFAC, Buisine M-Pierre, Claes K, Colas C, Fodde R, Fostira F, Franken PF, Gaustadnes M, Heinemann K, Hodgson SV, Hogervorst FBL, Holinski-feder E, Lagerstedt-robinson K, Olschwang S, Ouweland AMWVD, Redeker EJW, Scott RJ, Vankeirsbilck B, Grønlund RV, Wijnen JT, Wikman FP, Aretz S, Sampson JR, Devilee P, Dunnen JTD, Hes FJ: **Leiden Open Variation Database of the MUTYH Gene Human Mutation**. *Hum Mutat* 2010, **31**(11):1205-1215.
3. Nghiem Y, Cabrera M, Cupples CG, Miller JH: **The mutY gene: a mutator locus in Escherichia coli that generates G.C—T.A transversions**. *PNAS* 1988, **85**(8):2709-13.
4. Sampson JR, Jones S, Dolwani S, Cheadle JP: **MUTYH (MYH) and colorectal cancer**. *Biochem Soc Trans* 2005, **33**(4):679-683.
5. Nielsen M, Morreau H, Vasen HFA, Hes FJ: **MUTYH-associated polyposis (MAP)**. *Crit Rev Oncol Hematol* 2010, 1-16.
6. Sampson JR, Dolwani S, Jones S, Eccles D, Ellis A, Evans DG, Frayling I, Jordan S, Maher ER, Mak T, Maynard J, Pigatto F, Shaw J, Cheadle JP: **Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH**. *Lancet* 2003, **362**(9377):39-41.
7. Filipe B, Baltazar C, Albuquerque C, Fragoso S, Lage P, Vitoriano I, Mão de Ferro S, Claro I, Rodrigues P, Fidalgo P, Chaves P, Cravo M, Nobre Leitão C: **APC or MUTYH mutations account for the majority of clinically well-characterized families with FAP and AFAP phenotype and patients with more than 30 adenomas**. *Clin Genet* 2009, **76**:242-255.
8. Aretz S, Hes FJ: **Clinical utility gene card for: MUTYH-associated polyposis (MAP), autosomal recessive colorectal adenomatous polyposis**. *Eur J Hum Genet* 2010, 2-4.
9. Pitroski CE, Cossio SL, Koehler-Santos P, Graudenz M, Prolla JC, Ashton-prolla P: **Frequency of the common germline MUTYH mutations p.G396D and p.Y179C in patients diagnosed with colorectal cancer in Southern Brazil**. *Int J Colorectal Dis* 2011, 3:1-16.
10. Rouleau E, Zattara H, Lefol C, Noguchi T, Briau A, Buecher B, Bourdon V, Sobol H, Lidereau R, Olschwang S: **First large rearrangement in the MUTYH gene and attenuated familial adenomatous polyposis syndrome**. *Clin Genet* 2011, **80**:301-303.
11. Abeyasinghe SS, Chuzhanova N, Krawczak M, Ball EV, Cooper DN: **Translocation and gross deletion breakpoints in human inherited disease and cancer I: Nucleotide composition and recombination-associated motifs**. *Hum Mutat* 2003, **22**(3):229-44.
12. Korb J, Urban AE, Affourtit JP, Godwin B, Grubert F, Simons JF, Kim PM, Palejev D, Carriero NJ, Du L, Taillon BE, Chen Z, Tanzer A, Saunders ACE, Chi J, Yang F, Carter NP, Hurler ME, Weissman SM, Harkins TT, Gerstein MB, Egholm M, Snyder M: **Paired-End Mapping Reveals Extensive Structural Variation in the Human Genome**. *Science* 2007, **420**(318):420-426.
13. Perry GH, Ben-dor A, Tsalenko A, Sampas N, Rodriguez-revenga L, Tran CW, Scheffer A, Steinfeld I, Tsang P, Yamada NA, Park HS, Kim J-il, Seo J-sun, Yakhini Z, Laderman S, Bruhn L, Lee C: **The Fine-Scale and Complex Architecture of Human Copy-Number Variation**. *Am J Hum Genet* 2008, **82**:685-695.
14. Linardopoulou EV, Williams EM, Fan Y, Friedman C, Young JM, Trask BJ: **Human subtelomeres are hot spots of interchromosomal recombination and segmental duplication**. *Nature* 2005, **437**:94-100.
15. Chan CY, Kiechle M, Manivasakam P, Schiestl RH: **Ionizing radiation and restriction enzymes induce microhomology-mediated illegitimate recombination in Saccharomyces cerevisiae**. *Nuc Ac Res* 2007, **35**(15):5051-9.
16. Weaver DT, DePamphilis ML: **Specific Sequences in Native DNA that Arrest Synthesis by DNA Polymerase α** . *Biol Chem* 1982, **257**(4):2075-2086.
17. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, et al: **Initial sequencing and analysis of the human genome**. *Nature* 2001, **409**(6822):860-921.
18. Zelm MCV, Geertsema C, Nieuwenhuis N, Ridder DD, Conley ME, Schiff C, Tezcan I, Bernatowska E, Hartwig NG, Sanders EAM, Litzman J, Kondratenko I, Dongen JJMV, Burg MVD: **Gross Deletions Involving IGDM, BTK, or Artemis: A Model for Genomic Lesions Mediated by Transposable Elements**. *J Hum Genet* 2008, **82**: 320-332.
19. Franke G, Bausch B, Hoffmann MM, Cybulla M, Wilhelm C, Kohlhase J, Scherer G, Neumann HPH: **Alu-Alu recombination underlies the vast majority of large VHL germline deletions: Molecular characterization and genotype-phenotype correlations in VHL patients**. *Hum Mutat* 2009, **30**(5):776-86.
20. Kuiper RP, Vissers LELM, Venkatachalam R, Bodmer D, Hoenselaar E, Goossens M, Haufe A, Kamping E, Niessen RC, Hogervorst FBL, Gille JJP, Redeker B, Tops CMJ, van Gijn ME, van den Ouweland AMW, Rahner N, Steinke V, Kahl P, Holinski-Feder E, Morak M, Kloor M, Stemmler S, Betz B, Hutter P, Bunyan DJ, Syngal S, Culver JO, Graham T, Chan TL, Nagtegaal ID, et al: **Recurrence and variability of germline EPCAM deletions in Lynch syndrome**. *Hum Mutat* 2011, **32**(4):407-14.
21. Resta N, Giorda R, Bagnulo R, Beri S, Della Mina E, Stella A, Piglionica M, Susca FC, Guanti G, Zuffardi O, Ciccone R: **Breakpoint determination of 15 large deletions in Peutz-Jeghers subjects**. *Hum Genet* 2010, **128**(4):373-82.
22. Batzer MA, Deininger PL: **Alu repeats and human genomic diversity**. *Nat Rev Genet* 2002, **3**:370-379.
23. Chen H, Sun C, Guo W, Meng R, Du H, Qi Q, Gu X, Li L, Zhang K, Zhu D, Wang Y: **AluYb8 insertion in the MUTYH gene is related to increased 8-OHdG in genomic DNA and could be a risk factor for type 2 diabetes in a Chinese population**. *Mol Cell Endocrinol* 2011, **332**:301-305.

Pre-publication history

The pre-publication history for this paper can be accessed here:
<http://www.biomedcentral.com/1471-2350/12/128/prepub>

doi:10.1186/1471-2350-12-128

Cite this article as: Torrezan et al.: Breakpoint characterization of a novel large intragenic deletion of MUTYH detected in a MAP patient: Case report. *BMC Medical Genetics* 2011 **12**:128.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

